Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients
Files
Publication date
2016-01-01
Authors
Van Lelyveld, Steven F L
Symons, J
van Ham, P.M.
Connell, B. J.
Nijhuis, Monique
Wensing, Anne(marie)
Hoepelman, Andy
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
Available data on the use of maraviroc (MVC) in clinical settings are limited. In this cohort study, the clinical outcomes of HIV-1-infected patients treated with MVC were analysed and the predictive values of different tropism assays were compared. Baseline viral tropism was assessed and compared by phenotypic (Trofile and MT-2) and genotypic assays. Virological and immunological responses were evaluated. In total, 62 predominantly extensively pre-treated patients started MVC [median GSS 2.0 (IQR 2.0-2.5)]. Tropism assays were performed on baseline samples of 58 patients (93.5%). Thirty-two samples (80.0%) were classified as R5 by Trofile, 41 (80.4%) by genotypic tropism test (GTT) and 17 (81.0%) by MT-2. At least two types of tropism assay were performed on samples from 39 patients, whereas in 15 patients all three assays were performed (concordance 84.8-94.1%). Plasma HIV-RNA was
Keywords
CCR5 antagonist, HIV Infection, Human immunodeficiency virus, Maraviroc, Tropism, Taverne, Microbiology (medical), Infectious Diseases, Pharmacology (medical), Journal Article, Research Support, Non-U.S. Gov't
Citation
Van Lelyveld, S F L, Symons, J, Van Ham, P, Connell, B J, Nijhuis, M, Wensing, A M J & Hoepelman, A I M 2016, 'Clinical outcome of maraviroc-containing therapy in heavily pre-treated HIV-1-infected patients', International Journal of Antimicrobial Agents, vol. 47, no. 1, pp. 84-90. https://doi.org/10.1016/j.ijantimicag.2015.09.013